- Correction
- Open access
- Published:
Correction: Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making
BMC Cancer volume 23, Article number: 768 (2023)
The Original Article was published on 22 July 2023
Correction: BMC Cancer 23, 689 (2023)
Following publication of the original article [1], the authors reported that Figs. 4 and 5 were erroneously transposed. The original article [1] has been corrected.
A Expression of cardiac marker cardiac troponin (green-cTnT) in iPSCs-derived cardiomyocytes with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of cardiac troponin in iPSCs-derived Cardiomyocytes. B Representative calcium-flux signal traces (average fluorescence intensities) for cardiotoxic compound-Doxorubicin. Traces shown are typical phenotypic responses including unaffected regular Ca2+ flux patterns, and affected doxorubicin treated iPSC-derived cardiomyocytes (Control, Ovarian cancer and Breast cancer) patterns, Scale bar: 100 μm. C Representative calcium-flux signal traces (average fluorescence intensities) for chemotherapeutic cardiotoxic drugs. Traces shown are typical phenotypic responses including untreated regular Ca2+ flux patterns, and treated doxorubicin patterns
A Expression of glycogen storage (pink) and hepatic marker Albumin (green) in iPSCs-derived hepatocytes with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of Albumin in iPSCs-derived Hepatocytes. iPSC-derived hepatocytes (control, breast cancer and ovarian cancer patients) treated with Latrunculin showed sensitivity, Ovarian cancer and breast cancer hepatocytes showed more sensitivity than control. B Expression of endothelial marker CD31 (red-PECAM-1) in iPSCs-derived endothelial cells with nucleus (blue) was observed. Flowcytometry analysis showed more than 80% expression of CD31 in iPSCs-derived endothelial cells. Montage Image of in vitro angiogenesis assay on Matrigel revealed the potential to form capillary tubular networks of iPSC-ECs. Scale bar: 100 μm
References
Chitrangi S, Vaity P, Jamdar A, et al. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making. BMC Cancer. 2023;23:689. https://doi.org/10.1186/s12885-023-11078-9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12885-023-11078-9.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chitrangi, S., Vaity, P., Jamdar, A. et al. Correction: Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making. BMC Cancer 23, 768 (2023). https://doi.org/10.1186/s12885-023-11269-4
Published:
DOI: https://doi.org/10.1186/s12885-023-11269-4